Autologous platelet-rich gel combined with topical timolol in the treatment of diabetic foot ulcer : a randomized controlled study

Autologous platelet-rich gel combined with topical timolol in the treatment of diabetic foot ulcer: a randomized controlled study

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100048766

Enrollment

Unknown

Registered

2021-07-16

Start date

2021-07-25

Completion date

Unknown

Last updated

2022-03-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Foot

Interventions

intervention group:Autologous platelet-rich gel combined with timolol

control group:Autologous platelet-rich gel

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Patients with type 2 diabetes, meeting the 1999 WHO diagnostic criteria; 2.Patients with diabetic foot,meeting the 1999 WHO diagnostic criteria; 3.Patients aged 18-75 years; 4.The Wagner grade of diabetic foot is 2 to 3.

Exclusion criteria

Exclusion criteria: 1. Allergy or intolerance to APG or timolol; 2. Those who have taken beta-blockers or growth factor preparations within 1 month; 3. Bronchial asthma, atrioventricular block and other diseases or patients with heart rate 20cm2, ankle brachial index ABI < 0.5, or/and combined with acute osteomyelitis; 7. Women who are menstruating, pregnant or breastfeeding, those who abuse alcohol or drugs, and those who cannot cooperate with mental illnesses.

Design outcomes

Primary

Measure	Time frame
Shrink rate of ulcer;Ulcer healing time;total effective rate;	—

Countries

China

Contacts

Public ContactChen Zongcun

The Second Affiliated Hospital of Hainan Medical University

422731749@qq.com+86 15120884371

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026